

# CAMPBELL COUNTY MEMORIAL HOSPITAL

September 24, 1985

U.S. Nuclear Regulatory Commission  
Region IV  
611 Ryan Plaza Drive, Suite 1000  
Arlington, TX 76011

RE: Addition of a Designated User to Specific  
Nuclear Medicine License #49-18030-01

Gentlemen:

Please add Seymour J. Stifel, M.D. to the list of designated users of radio-isotopes at Campbell County Memorial Hospital. Enclosed are copies of Dr. Stifel's Curriculum Vitae, a copy of the Alabama license upon which Dr. Stifel was a designated user (see page 4, paragraph J), and a letter from Dr. Wilkinson at Duke University documenting Dr. Stifel's participation in the training program at Duke University Medical Center in 1971. Also enclosed is an Alabama preceptorship statement for Dr. Stifel executed by Dr. K&smodil.

Dr. Stifel has worked at Campbell County Memorial Hospital in Nuclear Medicine under my supervision since 6/15/85. He has demonstrated a more than adequate knowledge of radiation safety and radiation safety procedures as well as extremely good clinical knowledge in nuclear medicine. He is particularly adept at nuclear cardiology studies.

We do not have the details from Duke University to complete supplements A and B for form 313. If this is absolutely required we shall try to obtain same from Duke University. Considering the reputation of Duke University, we hope the attached letter from Dr. R.H. Wilkinson will be sufficient.

Sincerely,

*Max G. Walter*  
Max G. Walter, M.D.  
Radiation Safety Officer

Approved,

*Edward R. Frye, Jr.*  
Edward R. Frye, Jr.  
Administrator  
MGW:djh

8602060208 851209  
REG4 LIC30  
49-18030-01 PDR

RECEIVED BY

Date

Log

By

Orig. To

Action Compl.

**FEE EXEMPT**

Dedicated to Quality Health Care

P.O. BOX 3011

GILLETTE, WYOMING 82716

(307) 682-8811


**FEE EXEMPT**

760800

RECEIVED

'85 OCT -4 A6:54

EDWARD R. FRYE, JR.  
ADMINISTRATOR



CURRICULUM VITAE

NAME: Seymour J. Stifel, M.D.

BIRTHPLACE: New York, New, York

BIRTH DATE: December 5, 1939

SOCIAL SECURITY NUMBER: 074-30-7694

MARITAL STATUS: Divorced Two Children -- Ages 9 and 11

PRESENT ADDRESS: 4313 Little River Road  
Birmingham, Alabama 35213

EDUCATION: B.A. ----- Columbia University 1961

M.D. ----- The Chicago Medical School 1966

MILITARY SERVICE: USAF Regional Hospital  
Shaw Air Force Base, Sumter, S.C.  
1968 - 1970  
Radiologist

STATE LICENSES: California ----- 1967  
Illinois ----- 1967  
North Carolina-- 1970  
Alabama ----- 1972

SOCIETIES: RSNA  
Southeastern Angiographic Society  
Southeastern Neuro Radiological Society  
AMA (Jefferson County Medical Society)  
Birmingham Academy of Medicine

PROFESSIONAL AND ACADEMIC:

Rotating Internship -----Mt. Zion Hospital  
San Francisco, Cal.  
Diagnostic Radiology Residency -- Michael Reese Hospital  
Chicago, Ill. (1967-1969)  
Duke University Med. Center  
Durham, N.C. (1970-1973)  
Nuclear Medicine (3 months)-----Duke Hospital  
Durham, N.C. (April - June  
1971)  
Board Certified Diagnostic Radiology (This is including  
Nuclear Medicine) -----December 1973

X60800

Duke University Medical Center  
DURHAM, NORTH CAROLINA  
27710

IMAGING DIVISION  
DEPARTMENT OF RADIOLOGY  
P. O. BOX 3949

TELEPHONE (919) 884-1465

November 7, 1978

K. F. Kesmodel, M. D., F.A.C.R.  
Radiology Associates of Birmingham  
Professional Association  
Medical Towers Building  
1717 Eleventh Avenue, South  
Birmingham, Alabama 35205

RE: Seymour J. Stifel, M. D.


Dear Dr. Kesmodel:

I received your letter of October 2, 1978 today and I hope that the information I can provide will assist in resolving the licensure problem which Dr. Stifel is having in regards to the medical use of internally administered radioactive materials.

My records indicate that Dr. Stifel participated in our training program in Nuclear Medicine during the months of April 1971, May 1971 and June 1971. He participated at that time in the customary theoretical and practical experience in Nuclear Medicine which Radiology residents received on our service at that time. This formal training and experience has qualified other Radiology resident physicians who participated in our program at that time to receive approval from the Federal (ie. NRC) or appropriate State regulatory body to perform the Nuclear Medicine studies in which they participated during their training program. It would be difficult to provide specific figures for the studies performed during that time but this data can be "exhumed" from our stored records if necessary.

I hope the foregoing information plus the experience Dr. Stifel has had with you will be sufficient to satisfy the requirements for your State Regulatory body. Please extend my regards to Sy.

Sincerely yours,



R. H. Wilkinson, Jr., M. D.  
Nuclear Medicine Section  
Division of Imaging  
Department of Radiology  
Duke University Medical Center

RHWjr/lt

Supplement A

See attached letter from Duke

University

# **TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER		2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED TO PRACTICE		
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C		
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING	LOCATION AND DATE(S) OF TRAINING	TYPE AND LENGTH OF TRAINING		
		LECTURE/ LABORATORY COURSES (CLOCK HOURS)	SUPERVISED ON-THE-JOB EXPERIENCE (CLOCK HOURS)	
a. RADIATION PHYSICS AND INSTRUMENTATION				
b. RADIATION PROTECTION				
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY				
d. RADIATION BIOLOGY				
e. RADIOPHARMACEUTICAL CHEMISTRY				
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT USED AT ONE TIME	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE (CLOCK HOURS)	TYPE OF USE

## Supplement B (Continued)

PROPOSED PHYSICIAN USER

## PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

DATES OF TRAINING:

TOTAL NUMBER OF HOURS:

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		6. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR		7. PRECEPTOR'S NAME (Please type or print)	
b. NAME OF INSTITUTION			
c. MAILING ADDRESS			
d. CITY			
5. MATERIALS LICENSE NUMBER(S)		8. DATE	

## PRECEPTOR STATEMENT

## 1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME

STREET ADDRESS

CITY

STATE

ZIP CODE

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-76	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			



# ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH

## RADIOACTIVE MATERIAL LICENSE

AMENDMENT NO. 31

Pursuant to Alabama State Department of Public Health Regulations, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess and transfer radioactive material listed below; and to use such radioactive material for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules and regulations of the Alabama State Department of Public Health now or hereafter in effect and to any conditions specified below.

LICENSEE		In accordance with application dated 3. License number October 2, 1980, License No. 327 is amended in its entirety to read:	
1. Name	St. Vincent's Hospital	4. Expiration date	November 30, 1985
2. Address	2701 Ninth Court, South Birmingham, Alabama 35201	5. File no.	
6. Radioactive Material (Element and Mass Number)	7. Type of Radioactive Material License	8. Chemical and/or Physical Form	9. Maximum Radioactivity and/or quantity of ma- terial which licensee may possess at any one time.
SEE PAGE TWO	S	SEE PAGE TWO	SEE PAGE TWO
10. Authorized Use			
SEE PAGE THREE			

### CONDITIONS

11. Unless otherwise specified, the authorized place of use is the licensee's address stated in Item 2 above.
12. The licensee shall comply with the provisions of Part 6-1, General Provisions, Part 6-2, Licensing, Part 6-3, Standards for Protection Against Radiation, and Part 6-10, Notices, Instructions, and Reports to Workers; Inspections, of Alabama Regulations for Control of Radiation.
13. A. Radioactive material, except that listed in Subitem 6.I. shall be used by, or under the supervision of W. V. Weldon, M.D., or T. R. Cochran, M.D.
- B. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.G., 6.H., and 6.I., may also be used by, or under the supervision of G. L. Ricketts, M.D.
- C. Radioactive material, except that listed in Subitems 6.C., 6.E., 6.F., and 6.I., may also be used by, or under the supervision of K. F. Kesmodel, M.D., R. M. Doughton, M.D., or T. R. Cochran, M.D.

*See page 4*

# SUPPLEMENTARY SHEET

Continued From Page 1

License Number 327

Amendment Number 31

Radioactive Material  
(Element and mass number)

8. Chemical and/or Physical Form

9. Maximum Radioactivity and/or quantity of  
material which licensee may possess at  
any one time

A. Any radioactive material listed in Group I of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.

B. Any radioactive material listed in Groups II and III of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.

C. ✓ Gold 198

D. ✓ Phosphorus 32

E. ✓ Phosphorus 32

F. ✓ Gold 198

G. ✓ Iodine 131

H. ✓ Iodine 131

I. ✓ Iodine 125

J. Cesium 137

K. Cobalt 57

L. Radium 226

M. Barium 133

N. Cobalt 57

O. Technetium 99m

A. Any radiopharmaceutical listed in Group I of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.

B. Any radiopharmaceutical listed in Groups II and III of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.

C. Colloidal

D. Soluble Phosphate

E. Colloidal Chromic Phosphate

F. Seeds

G. Sodium Iodide

H. Sodium Iodide

I. Seeds

J. Any

K. Any

L. Sealed Source (Amersham/Searle Model 184622)

M. New England Nuclear Model NES-358

N. New England Nuclear Model NES-352

O. Labeled Sulfur Colloid

A. As necessary for uses authorized in Subitem 10.A.

B. As necessary for uses authorized in Subitem 10.B.

C. 300 millicuries

D. 40 millicuries

E. 40 millicuries

F. 300 millicuries

G. 150 millicuries

H. 30 millicuries

I. 50 millicuries

J. 50 microcuries

K. 200 microcuries

L. 19.3 microcuries

M. 260 microcuries

N. 115 microcuries

O. As necessary for uses authorized in Subitem 10.O.

460800



ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH  
RADIOACTIVE MATERIAL LICENSE

Continued

Supplementary Sheet

License Number 327Amendment Number 31

## CONDITIONS

10. Authorized Use

- A. Any diagnostic procedure listed in Group I of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.
- B. Any diagnostic procedure listed in Groups II and III of Schedule D, Part 6-2 of Alabama Regulations for Control of Radiation.
- C. Intracavitary treatment of pleural and peritoneal effusions and/or ascites. Intracavitary treatment of cancer.
- D. Treatment of polycythemia vera, leukemia, or metastasis in bone.
- E. Interstitial treatment of cancer.
- F. Interstitial treatment of cancer.
- G. Treatment of thyroid cancer or cardiac dysfunction.
- H. Treatment of hyperthyroidism.
- I. Interstitial treatment of cancer.
- J. Instrument calibration and product assay.
- K. Instrument calibration and product assay.
- L. Instrument calibration.
- M. Instrument calibration and product assay.
- N. Instrument calibration and product assay.
- O. Cystography as described in letter dated July 9, 1980.

ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH  
RADIOACTIVE MATERIAL LICENSE

Continued

Supplementary Sheet

License Number 327

Amendment Number 31

## CONDITIONS

- D. Radioactive material, except that listed in Subitems 6.F. and 6.I., may also be used by, or under the supervision of R. T. Ryan, M.D.
- E. Radioactive material, except that listed in Subitems 6.A., 6.C., 6.D., 6.F., 6.G., 6.H., and 6.I., may also be used by, or under the supervision of E. R. Meadows, M.D.
- F. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.E., and 6.F., may also be used by, or under the supervision of J. D. Glover, M.D.
- G. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.E., 6.F., 6.G., and 6.I., may also be used by, or under the supervision of G. P. Bergeron, M.D.
- H. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.E., 6.F., and 6.I., may also be used by, or under the supervision of D. B. Williams, M.D.
- I. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.E., 6.F., 6.H., and 6.I., may also be used by, or under the supervision of C. M. Eiland, M.D.
- J. Radioactive material, except that listed in Subitems 6.C., 6.D., 6.E., 6.F., 6.G., 6.H., and 6.I., may also be used by, or under the supervision of J. P. Mussleman, M.D., or S. J. Stifel, M.D.
- K. Radioactive material, except that listed in Subitems 6.A., 6.C., 6.D., 6.E., 6.F., 6.G., 6.H., and 6.I., may also be used by, or under the supervision of H. J. Thompson, M.D.
14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided:
- A. The visiting physician has the unrevoked written permission of the licensee's Administrator and Radioisotope Committee;
- B. The visiting physician does not perform any procedure which is not authorized for him to perform by the radioactive material license on which his name appears; and,
- C. A physician named in Condition 13 is in continued, active practice under this license.

460800

ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH  
RADIOACTIVE MATERIAL LICENSE

Continued

Supplementary Sheet

License Number 327Amendment Number 31

## CONDITIONS

The licensee shall maintain for inspection by the Agency, copies of the written permission specified in Subitem (A) above and of the license(s) specified in Subitems (B) and (C) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (A) above.

15. Radioactive material shall not be used in humans until its pharmaceutical quality and assay have been established.
16. Except as otherwise specifically provided by this license, radioactive material to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier who manufactures or repackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and nonpyrogenicity.
17. Biological products labeled with radionuclides or kits used to prepare such products shall be procured from a supplier who holds an unsuspended or unrevoked license issued by the Secretary, Department of Health, Education, and Welfare, to propagate, manufacture, prepare, label, or distribute the products.
18. Technetium 99m Pertechnetate shall be procured in separated, prepackaged, precalibrated form from a pharmaceutical supplier who manufactures the product under appropriate pharmaceutical controls related to assay, identity, quality, sterility, and pyrogenicity. Notwithstanding the foregoing requirement, Technetium 99m Pertechnetate may be eluted and prepared from a Molybdenum 99/Technetium 99m generator in accordance with statements, representations, and procedures contained in "Radioisotopes Radiation Safety Procedures Manual" dated October 2, 1980.
19. Technetium 99m labeled sulfur colloid preparations which appear flocculent or aggregated shall not be used in humans.
20. All kits from which radiopharmaceuticals are prepared shall be used in accordance with kit manufacturer's recommended procedures for preparation and use unless otherwise specified by this license.
21. Patients containing therapeutic quantities of Iodine 131 or Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH  
RADIOACTIVE MATERIAL LICENSE

Continued

Supplementary Sheet

License Number 327Amendment Number 31

## CONDITIONS

22. Except as specifically provided otherwise by this license, the licensee shall possess and use radioactive material described in Items 6, 8, and 9 of this license in accordance with statements, representations, and procedures contained in the following documents:

- A. Application dated October 2, 1980.
- B. "Radioisotope Radiation Safety Procedures Manual" dated October 2, 1980.

Date of Issuance November 5, 1980By: Ira L. MyersIra L. Myers, M. D.  
State Health Officer

ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH

460800

ALABAMA STATE DEPARTMENT OF PUBLIC HEALTH  
APPLICATION FOR RADIOACTIVE MATERIAL LICENSE  
SUPPLEMENT A - HUMAN USE

Licensee

St. Vincent's Hosp

# 327

Name of Physician

Seymour J. Stifel

## SCHEDULE OF RADIOACTIVE MATERIALS AND NUCLEAR MEDICINE QUALIFICATIONS

RADIOISOTOPE	FORM ADMINISTERED	SCANNING PROCEDURES	DOSE ADMINISTERED	ACTIVE CASES <sup>1</sup>	SCANS REVIEWED <sup>2</sup>	
					Normal	Total
Cr <sup>51</sup>	Chromate	Spleen imaging <i>sequestration</i>	250 $\mu$ Ci	1	8	14
Cr <sup>51</sup>	Chromate	Placenta Localization				
Cr <sup>51</sup>	Labeled Human Serum Albumin	Placenta Localization				
Au <sup>198</sup>	Colloidal	Liver imaging				
I <sup>131</sup>	Iodide	Thyroid imaging	50 $\mu$ Ci	5	25+	50+
I <sup>131</sup>	Iodinated Human Serum Albumin	Brain Tumor Localization				
I <sup>131</sup>	Iodinated Human Serum Albumin	Placenta Localization				
I <sup>131</sup>	Iodinated Human Serum Albumin	Cardiac imaging for Determination of Pericardial Effusion				
I <sup>131</sup>	Iodinated Human Serum Albumin	Cisternography				
I <sup>131</sup>	Rose Bengal	Liver imaging	300 $\mu$ Ci		2	2
I <sup>131</sup>	Labeled Renal Function Compound	Kidney imaging				
I <sup>131</sup>	Sodium Iodipamide	Cardiac imaging for Determination of Pericardial Effusion				
I <sup>131</sup>	Macroaggregated Iodinated Human Serum Albumin	Lung imaging				
I <sup>131</sup>	Colloid Microaggregated Iodinated Human Serum Albumin	Liver imaging				
Hg <sup>197</sup>	Chloromerodrin	Kidney imaging				
Hg <sup>197</sup>	Chloromerodrin	Brain imaging				
Hg <sup>203</sup>	Chloromerodrin	Brain imaging				
Hg <sup>203</sup>	Chloromerodrin	Kidney imaging				
Se <sup>75</sup>	Labeled Methionine	Pancreas imaging				
Sr <sup>85</sup>	Nitrate or Chloride	Bone Imaging on Patients with Diagnosed Cancer				
Xe <sup>133</sup>	Gas or Gas in Solution	Pulmonary Function Studies				
Xe <sup>133</sup>	Gas or Gas in Solution	Diagnosis of Cardiac Abnormalities				
Xe <sup>133</sup>	Gas or Gas in Solution	Blood Flow Studies				
Tc <sup>99m</sup>	Pertechnetate	Brain imaging	20 mCi	5	50+	100+
Tc <sup>99m</sup>	Pertechnetate	Thyroid imaging	5 mCi	2	10+	20+
Tc <sup>99m</sup>	Pertechnetate	Blood Pool imaging				
Tc <sup>99m</sup>	Pertechnetate	Salivary Gland imaging	15 mCi		2	2
Tc <sup>99m</sup>	Pertechnetate	Placenta Localization Studies				
Tc <sup>99m</sup>	Labeled Stannous Polyphosphate	Bone imaging	20 mCi	3	25+	50+
Tc <sup>99m</sup>	Labeled Sulfur Colloid	Liver imaging	3 mCi	3	50+	100+
Tc <sup>99m</sup>	Labeled Sulfur Colloid	Spleen imaging	3 mCi	3	50+	100+
Tc <sup>99m</sup>	D.T.P.A. (Iron-ascorbate)	Kidney imaging				
Tc <sup>99m</sup>	D.T.P.A. (Tio)	Brain imaging				
Tc <sup>99m</sup>	D.T.P.A. (Tin)	Kidney imaging	15 mCi		8	10
Tc <sup>99m</sup>	Human Serum Albumin Microspheres	Lung imaging	3 mCi	3	50+	100+
Ga <sup>67</sup>	Citrate	soft tissue imaging	6 mCi	2	10+	20+
Tc <sup>99m</sup>	diphosphonate	bone imaging	20 mCi	3	20+	40+
Yt <sup>169</sup>	DTPA	Cisternography	1 mCi	4	4	4

<sup>1</sup> ACTIVE CASES shall consist of: a) personal observation of complete procedure; and b) detailed discussion of the case including history and results of the procedure with the preceptor.

<sup>2</sup> SCANS REVIEWED shall consist of case file review and discussion of diagnosis with preceptor.

PRECEPTOR CERTIFICATION: I hereby affirm that the indicated clinical training and experience is true to the best of my knowledge.

Institution St. Vincent's Hosp

Signature of Preceptor *St. J. Stifel*

Date 11 Dec 78

Preceptor *ILF Hermodel Jr MD*

LICENSEE *St. J. Stifel* This physician will be permitted to use radioactive materials in accordance with the terms and conditions of license issued.

Signature (Hospital Administration)

Title

State

